193 related articles for article (PubMed ID: 33860275)
1. TFEB links MYC signaling to epigenetic control of myeloid differentiation and acute myeloid leukemia.
Yun S; Vincelette ND; Yu X; Watson GW; Fernandez MR; Yang C; Hitosugi T; Cheng CH; Freischel AR; Zhang L; Li W; Hou H; Schaub FX; Vedder AR; Cen L; McGraw KL; Moon J; Murphy DJ; Ballabio A; Kaufmann SH; Berglund AE; Cleveland JL
Blood Cancer Discov; 2021 Mar; 2(2):162-185. PubMed ID: 33860275
[TBL] [Abstract][Full Text] [Related]
2. Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy.
Fernandez MR; Schaub FX; Yang C; Li W; Yun S; Schaub SK; Dorsey FC; Liu M; Steeves MA; Ballabio A; Tzankov A; Chen Z; Koomen JM; Berglund AE; Cleveland JL
Cancer Res; 2022 Apr; 82(7):1234-1250. PubMed ID: 35149590
[TBL] [Abstract][Full Text] [Related]
3. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
[TBL] [Abstract][Full Text] [Related]
4. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy.
Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P
J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945
[TBL] [Abstract][Full Text] [Related]
5. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
[TBL] [Abstract][Full Text] [Related]
6. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.
Chen C; Liu Y; Lu C; Cross JR; Morris JP; Shroff AS; Ward PS; Bradner JE; Thompson C; Lowe SW
Genes Dev; 2013 Sep; 27(18):1974-85. PubMed ID: 24065765
[TBL] [Abstract][Full Text] [Related]
7. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia.
Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE
J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332
[TBL] [Abstract][Full Text] [Related]
9. ZFX controls propagation and prevents differentiation of acute T-lymphoblastic and myeloid leukemia.
Weisberg SP; Smith-Raska MR; Esquilin JM; Zhang J; Arenzana TL; Lau CM; Churchill M; Pan H; Klinakis A; Dixon JE; Mirny LA; Mukherjee S; Reizis B
Cell Rep; 2014 Feb; 6(3):528-40. PubMed ID: 24485662
[TBL] [Abstract][Full Text] [Related]
10. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
11. PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
Goswami S; Mani R; Nunes J; Chiang CL; Zapolnik K; Hu E; Frissora F; Mo X; Walker LA; Yan P; Bundschuh R; Beaver L; Devine R; Tsai YT; Ventura A; Xie Z; Chen M; Lapalombella R; Walker A; Mims A; Larkin K; Grieselhuber N; Bennett C; Phelps M; Hertlein E; Behbehani G; Vasu S; Byrd JC; Muthusamy N
Blood; 2022 Mar; 139(9):1340-1358. PubMed ID: 34788382
[TBL] [Abstract][Full Text] [Related]
12. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
Huang H; Jiang X; Wang J; Li Y; Song CX; Chen P; Li S; Gurbuxani S; Arnovitz S; Wang Y; Weng H; Neilly MB; He C; Li Z; Chen J
Cancer Lett; 2016 Mar; 372(2):157-65. PubMed ID: 26791235
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
14.
Pasca S; Jurj A; Tomuleasa C; Zdrenghea M
Medicina (Kaunas); 2020 Nov; 56(12):. PubMed ID: 33255417
[No Abstract] [Full Text] [Related]
15. c-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.
Su R; Gong JN; Chen MT; Song L; Shen C; Zhang XH; Yin XL; Ning HM; Liu B; Wang F; Ma YN; Zhao HL; Yu J; Zhang JW
Oncotarget; 2016 Nov; 7(47):77430-77443. PubMed ID: 27764807
[TBL] [Abstract][Full Text] [Related]
16. l-Asparaginase-mediated downregulation of c-Myc promotes 1,25(OH)
Song JH; Park E; Kim MS; Cho KM; Park SH; Lee A; Song J; Kim HJ; Koh JT; Kim TS
Int J Cancer; 2017 May; 140(10):2364-2374. PubMed ID: 28224619
[TBL] [Abstract][Full Text] [Related]
17. WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation.
Wang Y; Xiao M; Chen X; Chen L; Xu Y; Lv L; Wang P; Yang H; Ma S; Lin H; Jiao B; Ren R; Ye D; Guan KL; Xiong Y
Mol Cell; 2015 Feb; 57(4):662-673. PubMed ID: 25601757
[TBL] [Abstract][Full Text] [Related]
18. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
19. Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Chen EC; Li S; Eisfeld AK; Luskin MR; Mims A; Jones D; Antin JH; Cutler CS; Koreth J; Ho VT; Gooptu M; Romee R; El-Jawahri A; McAfee SL; DeFilipp Z; Soiffer RJ; Chen YB; Fathi AT
Transplant Cell Ther; 2021 Jun; 27(6):479.e1-479.e7. PubMed ID: 33840625
[TBL] [Abstract][Full Text] [Related]
20. [Research Advances of IDH2 Gene Mutation in Acute Myeloid Leukemia].
Zhao YX; Shen XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):632-6. PubMed ID: 27151043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
